Hck-IN-1
CAS No. : 1473404-51-1
| Size | Price | Stock |
|---|---|---|
| 5mg | $280 | In-stock |
| 10mg | $440 | In-stock |
| 50mg | $1050 | In-stock |
| 100mg | $1450 | In-stock |
| 200 mg | Get quote | |
| 500 mg | Get quote | |
| We match the lowest price on market. | ||
We offer a substantial discount on larger orders, please inquire via [email protected]
or Fax: (86)21-58955996
Inquiry for price and availability only. Please place your order via our email or fax.
| Cat. No. : | HY-125028 |
| M.Wt: | 402.81 |
| Formula: | C16H11ClN6O3S |
| Purity: | >98 % |
| Solubility: | DMSO : 12.5 mg/mL (ultrasonic) |
Hck-IN-1 (compound B9), a diphenylpyrazolo compound, is a selective Nef-dependent Hck inhibitor with IC50s of 2.8 μM, >20 μM for Nef:Hck complex and Hck, respectively. Hck-IN-1 is a direct and wide HIV-1 Nef antagonists with an IC50 of 100-300 nM for wild-type HIV-1 replication. Hck-IN-1 binds pocket residue Asn126 and has anti-retroviral activity[1].
IC50 & Target: IC50: 2.8 μM (Nef:Hck complex), >20 μM (Hck) and 100-300 nM (HIV-1 Nef)[1]
In Vitro: Hck-IN-1 (compound B9) shows weak activity against other Src-family members in vitro, with IC50 values >20 μM for c-Src, Lck and Lyn[1].
B9 (1 μM; 8 days) completely inhibits Nef-dependent SFK activation at a concentration of 1.0 μM[1].
Hck-IN-1 (0.1, 0.3, 1, 3 μM) also inhibits Nef-mediated enhancement of HIV-1 infectivity in a concentration-dependent manner in the reporter cell line, TZM-bl[1].
Hck-IN-1 inhibits the replication of all eleven HIV-1 Nef chimeras with IC50 values of ~ 300 nM in CEM-T4 cells, demonstrating that the compound is broadly active against HIV replication supported by a wide range of HIV-1 Nef proteins[1].
Lorem ipsum dolor sit amet, consectetur adipisicing elit. Autem earum hic iste maiores, nam neque rem suscipit. Adipisci consequatur error exercitationem fugit ipsam optio qui, quibusdam repellendus sed vero! Debitis.
Inquiry Information- Product Name:
- Hck-IN-1
- Cat. No.:
- HY-125028
- Quantity:
Your information is safe with us.